Pharma Mar (OTCMKTS:PHMMF – Get Free Report) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 252 shares, a decline of 99.3% from the June 15th total of 34,651 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. Approximately 0.0% of the shares of the company are sold short.
Pharma Mar Stock Down 3.6%
PHMMF traded down $3.44 during trading on Friday, reaching $90.90. 102 shares of the company were exchanged, compared to its average volume of 27. The firm has a 50 day moving average of $95.96 and a 200 day moving average of $93.82. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. Pharma Mar has a 52 week low of $77.41 and a 52 week high of $110.40.
Analysts Set New Price Targets
PHMMF has been the topic of a number of recent research reports. Zacks Research upgraded shares of Pharma Mar to a “hold” rating in a research report on Monday, June 15th. BTIG Research began coverage on shares of Pharma Mar in a research report on Thursday, April 23rd. They set a “buy” rating for the company. Finally, Chardan Capital upgraded shares of Pharma Mar to a “strong-buy” rating in a research note on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Pharma Mar currently has a consensus rating of “Buy”.
About Pharma Mar
PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.
The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.
Featured Articles
- Five stocks we like better than Pharma Mar
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.
